Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIP subcutaneous benzathine penicillin G for rheumatic fever and rheumatic heart disease
ACTRN12626001106325Phase 2Not yet recruiting
- Sponsor
- The Kids Research Institute Australia
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benzylpenicillin in rheumatic fever (RF) and rheumatic heart disease (RHD), sponsored by The Kids Research Institute Australia. Primary endpoints: The acceptability of SCIP implementation, The self-reported tolerability of SCIP administration and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
benzylpenicillin
03
Conditions
rheumatic fever (RF)rheumatic heart disease (RHD)
Beyond the preview
Go deeper on ACTRN12626001106325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001106325.